Federal Register Notices
View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.
| View | Date Published | Title | Comments Close On | Dates |
|---|---|---|---|---|
| View | Prospective Grant of Exclusive License: Development of Ocular Therapeutics Utilizing the Peptide C16Y and Related Peptides | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 18, 2012 will be considered. | ||
| View | Prospective Grant of Exclusive License: P4 Peptide From Streptococcus Pneumoniae | 5/19/2005. | ||
| View | Prospective Grant of Exclusive License: Development of Oncolytic Viral Cancer Therapies | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 14, 2012 will be considered. | ||
| View | Prospective Grant of Exclusive License: Method for Segmenting Medical Images and Detecting Surface Anomalies in Anatomical Structures | Only written comments and/or application for a license that are received by the NIH Office of Technology Transfer on or before May 10, 2012 will be considered. | ||
| View | Prospective Grant of Exclusive License: Family Healthware | 2/3/2005. | ||
| View | Prospective Grant of Exclusive License: Photosensitizing Antibody-Fluorophore Conjugates for Photo-Immunotherapy | Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before March 5, 2012 will be considered. | ||
| View | Prospective Grant of Exclusive License: The Development of Human Anti-CD22 Monoclonal Antibodies for the Treatment of Human Cancers and Autoimmune Disease | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before March 5, 2012 will be considered. | ||
| View | Prospective Grant of Exclusive License: The Development of Anti-mesothelin Targeted Immunotoxins for the Treatment of Cancer | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before March 15, 2012 will be considered. | ||
| View | Prospective Grant of Exclusive License: The Development of Human Anti-Mesothelin Monoclonal Antibodies for the Treatment of Human Cancers | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before February 16, 2012 will be considered. | ||
| View | Prospective Grant of Exclusive License: Development of T Cell Receptors and Chimeric Antigen Receptors Into Therapeutics for Adoptive Transfer in Humans To Treat Cancer | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before February 23, 2012 will be considered, in addition to the current non- exclusive applications under consideration, for the prospective license territory and field of use to be granted under the contemplated exclusive patent license. | ||
| View | Prospective Grant of Exclusive License: Use of Methanocarba Analogues of Purine and Pyrimidine Nucleosides and Nucleotides to Treat or Prevent Cardiac Diseases in Humans | Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before January 11, 2012 will be considered. | ||
| View | Prospective Grant of Exclusive License: Veterinary Biological Products for Swine Influenza Vaccines | Only written comments and/or application for a license that are received by the NIH Office of Technology Transfer on or before January 20, 2012 will be considered. | ||
| View | Prospective Grant of Exclusive License: Avian Influenza Vaccines for Domesticated Poultry/Wild Birds To Be Provided to the National Veterinary Stockpile Program and Avian Influenza Vaccines To Be Sold as Veterinary Biological Products | Only written comments and/or application for a license that are received by the NIH Office of Technology Transfer on or before January 5, 2012 will be considered. | ||
| View | Prospective Grant of Exclusive License: Use of Agents Targeting Thrombospondin-1 and CD47 To Treat Radiation-Induced Damage and Enhance the Effectiveness of Radiotherapy in Cancer Patients | Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before January 9, 2012 will be considered. | ||
| View | Prospective Grant of Exclusive License: Development of Cannabinoid(s) and Cannabidiol(s) Based Therapeutics To Treat Hepatic Encephalopathy in Humans. | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before December 19, 2011 will be considered. | ||
| View | Prospective Grant of Exclusive License: Electron Paramagnetic Resonance Devices and Systems for Oximetry | Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before November 15, 2011 will be considered. | ||
| View | Government-Owned Inventions; Licensing and Collaborative Research Opportunity for PANVAC-Cancer Vaccine for the Prevention and Treatment of Colorectal Cancer | |||
| View | Prospective Grant of Exclusive License: The Development of a Companion Diagnostic Kit for Predicting Therapeutic Efficacy of Anti-Cancer Agents | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before November 21, 2011 will be considered. | ||
| View | Prospective Grant of Exclusive License: The Development of Human Anti-Mesothelin Monoclonal Antibodies for the Treatment of Human Cancers | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before November 14, 2011 will be considered. | ||
| View | Prospective Grant of Exclusive License: Secreted Frizzled Related Protein-1 (sFRP-1) and derivatives thereof and their Use In Therapeutic Applications | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before November 14, 2011 will be considered. | ||
| View | Prospective Grant of Exclusive License: Compositions and Method for Preventing Reactogenicity Associated with Administration of Immunogenic Live Rotavirus Compositions | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before October 31, 2011 will be considered. | ||
| View | Prospective Grant of Exclusive License: Conjugate Vaccines Against B. anthracis (Anthrax) and Monoclonal Antibodies Against Anthrax | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before September 26, 2011 will be considered. | ||
| View | Prospective Grant of Exclusive License: Devices for Clearing Mucus From Endotracheal Tubes | Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before September 23, 2011 will be considered. | ||
| View | Prospective Grant of Exclusive License: Use of PKM2 Activators for the Treatment of Cancer | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before September 7, 2011 will be considered. | ||
| View | Government-Owned Inventions; Availability for Licensing |